Analyst Thomas Shrader from BTIG maintained a Buy rating on Alto Neuroscience, Inc. and keeping the price target at $28.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Thomas Shrader has given his Buy rating due to a combination of factors tied to Alto Neuroscience’s advancing clinical pipeline and de-risked trial design. He highlights ALTO-207 as a key long-term value driver, noting that its active component has shown roughly double the effect of standard therapies in treatment-resistant depression, with an adjunct agent expected to mitigate side effects and potentially create a highly differentiated product.
Shrader also emphasizes nearer-term catalysts from three precision-psychiatry programs—ALTO-101 in CIAS, ALTO-300 in MDD, and ALTO-100 in bipolar depression—where improved patient compliance and biomarker-driven selection could unlock meaningful efficacy signals. In addition, he points to ALTO-101 as an important proof-of-concept, using a validated EEG biomarker and a cognitive endpoint in an underserved schizophrenia population, while Alto’s cash runway into 2028 provides sufficient capital to reach several major data readouts, supporting the Buy recommendation.
According to TipRanks, Shrader is a 4-star analyst with an average return of 6.1% and a 39.92% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Invivyd, Opus Genetics, and Vaxcyte.
In another report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $30.00 price target.